A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity
Lutz Müller(Roche (Switzerland)), Larry P. Yotti(University of Vermont), Sheila M. Galloway(United States Military Academy), Betsy Fritschel(Johnson & Johnson (United States)), Ganapathy Mohan(Sanofi (United States)), John D. Mackinnon(GlaxoSmithKline (United Kingdom)), Charles Humfrey(AstraZeneca (United Kingdom)), Robert J. Mauthe(Pfizer (United States)), Chris Beels(GlaxoSmithKline (United Kingdom)), Christopher M. Riley(University of Strathclyde), Daniel Ness(Eli Lilly (United States)), Gopi Vudathala, Marta M. Andino(Pfizer (United States)), Alfons G. M. De Knaep(Janssen (Belgium)), David De Antonis(Pfizer (United States)), Dean Ellison(United States Military Academy), Rebecca D. Frank, Mark D. Smith, Joseph J. DeGeorge(United States Military Academy), Jane A. Fagerland(Abbott Fund), Michael R. O’Donovan, Nirdosh K. Jagota, Ernie Harpur(Sanofi (United States)), Alexander S. Jacks
Cited by 461
Related Papers
Chromosome aberrations and sister chromatid exchanges in chinese hamster ovary cells: Evaluations of 108 chemicals
|Environmental and Molecular Mutagenesis|1987|661
Skin Tumor-Promoting Activity of Benzoyl Peroxide, a Widely Used Free Radical-Generating Compound
|Science|1981|507
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster
|Proceedings of the National Academy of Sciences|2000|221